Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UC San Diego
La Jolla, CA
Uri Elkayam, MD, FACC, FAHA, FHFSA
Professor of Medicine
Professor of Obstetrics and Gynecology
Director Maternal Cardiology
University of Southern California
Los Angeles, CA
Gregg Fonarow, MD, FACC, FAHA, FHFSA
The Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson – UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Interim Chief, UCLA Division of Cardiology
David Geffen School of Medicine
Los Angeles, CA
J. Thomas Heywood, MD
Advanced Heart Failure and Transplant Cardiology,
Cardiovascular Disease,
Adult Comprehensive Echocardiography
Scripps Health
San Diego, CA
Athena Philis-Tsimikas, MD
Corporate Vice President, Scripps Whittier Diabetes Institute
Scripps Health
Director, Community Engagement, Scripps Research Translational Institute
San Diego, CA
Matthew J. Price, MD
Professor of Medicine
Director, Cardiac Catheterization Laboratory
Division of Cardiovascular Diseases
Department of Medicine
Scripps Clinic
San Diego, CA
Eric Adler, MD, FACC
Professor of Medicine
The Czarina and Humberto S. Lopez Chancellors Endowed Chair in Cardiology
Director Strauss Center for Cardiomyopathy & Section Head Heart Failure
Laith Alshawabkeh, MD, MSCI, FACC
Associate Professor of Clinical Medicine
Director, Adult Congenital Heart Program
Antoinette S. Birs, MD
Advanced Heart Failure and Transplant Cardiology
Lori Daniels, MD, MAS, FACC, FAHA
Medical Director, Cardiovascular Intensive Care Unit
Professor of Medicine
Division of Cardiovascular Medicine
Kimberly N. Hong, MD, MHSA
Assistant Professor of Medicine
Advanced Heart Failure,
Heart Transplant and Mechanical Circulatory Support
Jonathan C. Hsu, MD, MAS
Professor of Medicine
Section of Cardiac Electrophysiology
Division of Cardiology
Trina Huynh, PharmD, BCPS
Transitions of Care Coordinator
Department of Pharmacy
Jade Kozuch, PharmD, BCTXP
Pharmacist Specialist
Cardiothoracic Transplant and Mechanical Circulatory Support
David E. Krummen, MD, FACC, FHRS
Director of Electrophysiology,
VA San Diego Healthcare System
Professor of Medicine
Julia McCain, PA-C
Advanced Heart Failure
Melissa Mclenon, NP
Nurse Practitioner, Surgery
Anya Narezkina, MD
Associate Clinical Professor of Medicine
Director, Cardio-Oncology Program
Demos Papamatheakis, MD
Professor of Clinical Medicine
Pulmonary Vascular Section
Pulmonary, Critical Care, Sleep Medicine and Physiology
Hilary Shapiro, MD, MSc
Assistant Clinical Professor of Medicine
Advanced Heart Failure and Transplant Cardiology
Jia Shen, MD, MPH, FACC
Associate Professor of Medicine
Director Bankers Hill Cardiovascular Clinics
Department of Cardiology
Jorge Silva Enciso, MD, FACC
Clinical Professor of Medicine
Director, Hypertrophic Cardiomyopathy Program
Heart Failure, Mechanical Circulatory Support and Transplant Cardiology
Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine
Hao (Howie) Tran, MD, FACC
Associate Professor of Medicine
Director, Heart Failure Services
Director, Cardiogenic Shock and Mechanical Circulatory Support
Division of Cardiovascular Medicine
Marcus Anthony Urey, MD
Associate Professor of Medicine
Department of Medicine
Nicholas Wettersten, MD, FACC
Assistant Clinical Professor of Medicine
Department of Cardiology
Michael J. Wilkinson, MD, FACC
Assistant Clinical Professor of Medicine
Division of Cardiovascular Medicine
Andrew Willeford, PharmD, PhD, BCCP
Health Sciences Assistant Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.